NVIDIA-backed AI drugmaker Iambic seeks US IPO, plans to raise up to $159 million

US biopharmaceutical company Iambic Therapeutics has filed for an initial public offering of 9.375 million shares of common stock at a price range of $15 to $17 per share, aiming to raise approximately $141 million to $159 million. Founded in 2019, the company has raised $461.8 million from investors in technology and healthcare since then. Its major shareholders include US investment firms Catalio Capital Management, Nexus Venture Partners, and Coatue, as well as NVIDIA and the healthcare-focused investment arm of Qatar Investment Authority.